FDA Seeks Input On How To Identify, Measure Disease Symptoms Most Meaningful For Patients

FDA will host a two-day patient-focused drug development meeting in October in a bid to better understand how to identify what is most important to patients and caregivers with regard to burdens associated with diseases and disease treatment; benefits and risks when managing a patient’s disease; and using fit-for-purpose clinical outcome assessments (COAs) to measure patient experience in clinical trials, the agency announced Friday (Aug. 10).